About Us

Crescendo Biologics is focused on novel T cell enhancing therapeutics in immuno-oncology

Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. The lead programme, CB307, is a first in class PSMA x CD137 (4-1BB) bispecific molecule. Behind the lead programme there is a pipeline of other first or best in class CD137 (4-1BB) bispecifics for the treatment of cancers, targeting MSLN, 5T4 and ROR1.

T cell enhancing pipeline advantages:

  • Enhanced safety via conditional activation of only tumour-specific T cells, localised in the tumour micro-environment
  • Proliferation of tumour-specific T cells to drive a broad tumour cell killing
  • Survival of tumour-specific T cells for a more durable anti-cancer effect (‘memory’ responses)

Crescendo is also developing CB213, a preclinical PD-1 x LAG-3 multi-specific Humabody which has been designed to deliver safer, more effective therapeutic intervention in patients with cancers resistant or refractory to PD-1 blockade alone. The preclinical pharmacology of CB213 has been published in the British Journal of Cancer.

Crescendo’s pipeline is underpinned by its novel, patent-protected Humabody® VH platform.

Some of the key Humabody VH platform benefits include:

  • Rapid discovery process
  • Fully human VH domains (Humabodies) – no humanisation step is required
  • Exceptional diversity and excellent hit rates
  • Small size with ability to reach epitopes that monoclonal antibodies cannot
  • Clearly differentiated tissue accumulation and tissue penetration compared to conventional monoclonal antibodies
  • Robust chemical and physical stability
  • Easily assembled into multi-specific formats (MultiBody®s), which can be formatted to access novel biology
  • Tuneable half-life
  • Multiple administration routes
  • Excellent expression yields and established manufacturing processes

Beyond Crescendo’s proprietary pipeline, the Company has global, multi-target discovery and development collaborations with both Takeda and BioNTech and an exclusive, worldwide licensing agreement with Zai Lab.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, BioNTech, Takeda and Quan Capital.